Literature DB >> 12641733

Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.

Susi Keck1, Robert Nitsch, Tilman Grune, Oliver Ullrich.   

Abstract

Alzheimer's disease (AD) is characterized neuropathologically by intracellular neurofibrillary tangles (NFTs) formed of tau-based paired helical filaments (PHFs) and extracellular beta-amyloid plaques. The degree of Alzheimer dementia correlates with the severity of PHFs and NFTs. As an intraneuronal accumulation of oxidatively damaged proteins has been found in the brains of patients with AD, a dysfunction of the proteasomal system, which degrades damaged proteins, has been assumed to cause protein aggregation and therefore neurodegeneration in AD. In this study, we revealed that such proteasome dysfunction in AD brain results from the inhibitory binding of PHF-tau to proteasomes. We analysed the proteasome activity in brains from patients with AD and age-matched controls, and observed a significant decrease to 56% of the control level in the straight gyrus of patients with AD. This loss of activity was not associated with a decrease in the proteasome protein. PHF-tau co-precipitated during proteasome immunoprecipitation and proteasome subunits could be co-isolated during isolation of PHFs from AD brain. Furthermore, the proteasome activity in human brains strongly correlated with the amount of co-precipitated PHF-tau during immunoprecipitation of proteasome. Incubation of isolated proteasomes with PHF-tau isolated from AD brain, and with PHFs after in vitro assembly from human recombinant tau protein, resulted in a distinct inhibition of proteasome activity by PHF-tau. As this inhibition of proteasome activity was sufficient to induce neuronal degeneration and death, we suggest that PHF-tau is able directly to induce neuronal damage in the AD brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641733     DOI: 10.1046/j.1471-4159.2003.01642.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  148 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation.

Authors:  Dalia Halawani; Sylvain Tessier; Dominique Anzellotti; David A Bennett; Martin Latterich; Andréa C LeBlanc
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 4.  Integration of clearance mechanisms: the proteasome and autophagy.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-11-10       Impact factor: 10.005

5.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

Review 6.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

Review 7.  Regulation of proteasome activity in health and disease.

Authors:  Marion Schmidt; Daniel Finley
Journal:  Biochim Biophys Acta       Date:  2013-08-27

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.

Authors:  Xiangyou Hu; Qi Shi; Xiangdong Zhou; Wanxia He; Hong Yi; Xinghua Yin; Marla Gearing; Allan Levey; Riqiang Yan
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.